Nexeon Medsystems (OTCMKTS:NXNN)‘s stock had its “speculative buy” rating restated by equities research analysts at Taglich Brothers in a research note issued to investors on Tuesday. Taglich Brothers also issued estimates for Nexeon Medsystems’ Q4 2017 earnings at ($0.03) EPS, FY2017 earnings at ($0.14) EPS, Q1 2018 earnings at ($0.03) EPS, Q2 2018 earnings at ($0.03) EPS, Q3 2018 earnings at ($0.03) EPS, Q4 2018 earnings at ($0.04) EPS and FY2018 earnings at ($0.13) EPS.
Shares of Nexeon Medsystems (OTCMKTS NXNN) remained flat at $$1.01 during mid-day trading on Tuesday. The firm has a market capitalization of $27.50 and a PE ratio of -5.61. Nexeon Medsystems has a 12 month low of $0.40 and a 12 month high of $2.50.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/12/taglich-brothers-reaffirms-speculative-buy-rating-for-nexeon-medsystems-nxnn.html.
Nexeon MedSystems, Inc is a bioelectronics company developing active medical devices for the treatment of cardiovascular disease. The Company’s developing technology solutions device including electronics, software, mechanical engineering, and material science, as well as pharmaceuticals, protein chemistry, and cell biology.
Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.